Log in

NASDAQ:ARDSAridis Pharmaceuticals Stock Price, Forecast & News

+0.73 (+10.25 %)
(As of 08/7/2020 04:00 PM ET)
Today's Range
Now: $7.85
50-Day Range
MA: $6.86
52-Week Range
Now: $7.85
Volume303 shs
Average Volume12,728 shs
Market Capitalization$70.02 million
P/E RatioN/A
Dividend YieldN/A
Aridis Pharmaceuticals, Inc., a late-stage biopharmaceutical company, focuses on the discovery and development of targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections. Its lead product candidate is AR-301, a fully human mAb of immunoglobulin 1 (IgG1) that is in Phase III pivotal trials for the treatment of lung infections resulting from S. aureus alphatoxin. The company is also developing AR-105, a fully human IgG1 mAb, which is in Phase II trials to target gram-negative bacteria P. aeruginosa; AR-101, a human IgM mAb that is in Phase IIa trials for the treatment of hospital-acquired pneumonia (HAP)and ventilator-associated pneumonia (VAP) caused by P. aeruginosa serotype O11; AR-401 to treat infections caused by A. baumannii; AR-201, an anti- respiratory syncytial virus F-protein mAb; and AR-501, an anti-infective therapy to manage chronic lung infections in cystic fibrosis patients and acute pneumonia in HAP and VAP patients. Aridis Pharmaceuticals, Inc. was founded in 2003 and is headquartered in San Jose, California.
Read More
Aridis Pharmaceuticals logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.29 out of 5 stars

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:ARDS



Sales & Book Value

Annual Sales$1.02 million
Book Value$0.41 per share


Net Income$-29,680,000.00


Market Cap$70.02 million
Next Earnings Date8/10/2020 (Estimated)
OptionableNot Optionable
+0.73 (+10.25 %)
(As of 08/7/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ARDS News and Ratings via Email

Sign-up to receive the latest news and ratings for ARDS and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Aridis Pharmaceuticals (NASDAQ:ARDS) Frequently Asked Questions

How has Aridis Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Aridis Pharmaceuticals' stock was trading at $6.46 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, ARDS stock has increased by 21.5% and is now trading at $7.85.
View which stocks have been most impacted by Coronavirus

Do Wall Street analysts recommend investors buy shares of Aridis Pharmaceuticals?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aridis Pharmaceuticals in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Aridis Pharmaceuticals

When is Aridis Pharmaceuticals' next earnings date?

Aridis Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Monday, August 10th 2020.
View our earnings forecast for Aridis Pharmaceuticals

How were Aridis Pharmaceuticals' earnings last quarter?

Aridis Pharmaceuticals Inc (NASDAQ:ARDS) released its quarterly earnings data on Tuesday, May, 12th. The company reported ($0.73) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.67) by $0.06.
View Aridis Pharmaceuticals' earnings history

What price target have analysts set for ARDS?

5 analysts have issued 1 year price objectives for Aridis Pharmaceuticals' shares. Their forecasts range from $11.00 to $22.00. On average, they anticipate Aridis Pharmaceuticals' share price to reach $16.60 in the next year. This suggests a possible upside of 111.5% from the stock's current price.
View analysts' price targets for Aridis Pharmaceuticals

Has Aridis Pharmaceuticals been receiving favorable news coverage?

Headlines about ARDS stock have been trending negative on Saturday, InfoTrie Sentiment Analysis reports. The research firm identifies negative and positive press coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Aridis Pharmaceuticals earned a daily sentiment score of -2.5 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the company's share price in the next several days.
View the latest news about Aridis Pharmaceuticals

Are investors shorting Aridis Pharmaceuticals?

Aridis Pharmaceuticals saw a decline in short interest in July. As of July 31st, there was short interest totaling 26,200 shares, a decline of 6.1% from the July 15th total of 27,900 shares. Based on an average daily trading volume, of 10,600 shares, the short-interest ratio is currently 2.5 days. Currently, 0.5% of the shares of the stock are short sold.
View Aridis Pharmaceuticals' Short Interest

Who are some of Aridis Pharmaceuticals' key competitors?

What other stocks do shareholders of Aridis Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Aridis Pharmaceuticals investors own include Juno Therapeutics (JUNO), Gilead Sciences (GILD), VBI Vaccines (VBIV), Cidara Therapeutics (CDTX), Inovio Pharmaceuticals (INO), Sanofi (SNY), Dynavax Technologies (DVAX), (MRNA), Matinas BioPharma (MTNB) and Ocular Therapeutix (OCUL).

Who are Aridis Pharmaceuticals' key executives?

Aridis Pharmaceuticals' management team includes the following people:
  • Dr. Eric J. Patzer, Exec. Chairman (Age 71, Pay $233.12k)
  • Dr. Vu L. Truong, Founder, CEO & Director (Age 56, Pay $652.5k)
  • Mr. Fred Kurland, Consultant (Age 69, Pay $226.19k)
  • Mr. Michael A. Nazak, Chief Financial Officer (Age 61)
  • Mr. Jeffrey J. Fessler Esq., J.D., Acting Gen. Counsel (Age 57)

When did Aridis Pharmaceuticals IPO?

(ARDS) raised $28 million in an initial public offering (IPO) on Tuesday, August 14th 2018. The company issued 2,000,000 shares at a price of $13.00-$15.00 per share. Cantor served as the underwriter for the IPO and Maxim Group and Northland Capital Markets were co-managers.

What is Aridis Pharmaceuticals' stock symbol?

Aridis Pharmaceuticals trades on the NASDAQ under the ticker symbol "ARDS."

How do I buy shares of Aridis Pharmaceuticals?

Shares of ARDS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Aridis Pharmaceuticals' stock price today?

One share of ARDS stock can currently be purchased for approximately $7.85.

How big of a company is Aridis Pharmaceuticals?

Aridis Pharmaceuticals has a market capitalization of $70.02 million and generates $1.02 million in revenue each year. The company earns $-29,680,000.00 in net income (profit) each year or ($3.51) on an earnings per share basis. Aridis Pharmaceuticals employs 25 workers across the globe.

What is Aridis Pharmaceuticals' official website?

The official website for Aridis Pharmaceuticals is www.aridispharma.com.

How can I contact Aridis Pharmaceuticals?

Aridis Pharmaceuticals' mailing address is 5941 Optical Ct, San Jose CA, 95138. The company can be reached via phone at 408-385-1742 or via email at [email protected]

This page was last updated on 8/8/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.